Olverembatinib (HQP1351): a third-generation tyrosine kinase inhibitor in the treatment of hematologic and solid malignancies—a comprehensive review of clinical outcomes

Key Points

• Olverembatinib demonstrates promising clinical outcomes in treating hematologic and solid malignancies.
• Key evidence includes improved response rates reported across various studies, showing an efficacy rate of up to 80%.
• The assessment follows a comprehensive review of clinical outcomes based on multi-center trials and case reports.
• Further validation in larger patient populations is necessary to confirm these findings and optimize treatment protocols.